Indian pharmaceutical stocks may experience a potential resurgence in 2024, driven by increasing exports, strategic shifts in global markets, and a rising demand for affordable healthcare. Let’s explore the key drivers behind this resurgence and highlight the companies to watch as the industry charts a promising path forward.

What will it take to have a repeat of the past decade in India? Understand the essential factors, emerging trends, and potential hurdles that could influence India’s growth curve to replicate its past market success.

Regarding personal finance and investments, mutual funds, especially equity funds, always have an interesting discussion. The equity market is on a bull run, with the Sensex and Nifty touching new highs

The stage is set for the water infra industry as Budget 2024 floods the space with massive funding. Here’s what you need to know…

Brainbees Solutions Limited, which operates the FirstCry retail platform, will launch its IPO on the 6th of August consisting of a fresh issue and an offer for sale.

As buyback fever sweeps through Dalal Street, let’s examine how to approach the upcoming buyback season using a couple of past examples.

As Ola Electric Mobility Limited gears up for its IPO, find out how it stands on various metrics against its listed industry peers.

Akums Drugs and Pharmaceuticals Limited is one of India’s leading CDMO companies with a diverse client base and strategic presence.

Akums Drugs and Pharmaceuticals Limited will launch its IPO on 30th July with the issue size amounting up to ₹1,856.74 crores in the upper price band.

The recent announcement by JP Morgan about the inclusion of Indian government bonds in its Government Bond Index-Emerging Markets (GBI-EM) has sparked significant interest among investors. This move, officially included in June 2024, holds substantial implications for both the economy and retail investors. Read on to explore what this inclusion means and how it might shape financial landscapes.